MX2010008423A - Tratamiento de infecciones microbianas. - Google Patents

Tratamiento de infecciones microbianas.

Info

Publication number
MX2010008423A
MX2010008423A MX2010008423A MX2010008423A MX2010008423A MX 2010008423 A MX2010008423 A MX 2010008423A MX 2010008423 A MX2010008423 A MX 2010008423A MX 2010008423 A MX2010008423 A MX 2010008423A MX 2010008423 A MX2010008423 A MX 2010008423A
Authority
MX
Mexico
Prior art keywords
treatment
microbial infections
directed
mscramm
present
Prior art date
Application number
MX2010008423A
Other languages
English (en)
Inventor
Timothy Foster
Judy Higgins
Elisabeth Josefsson
Joan Geoghegan
Andrej Tarowski
Original Assignee
Trinity College Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40512496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010008423(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0801768.3A external-priority patent/GB0801768D0/en
Application filed by Trinity College Dublin filed Critical Trinity College Dublin
Publication of MX2010008423A publication Critical patent/MX2010008423A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige a mejorar vacunas de antígenos microbianos, composiciones farmacéuticas, composiciones inmunogénicas y anticuerpos y su uso en el tratamiento de infecciones microbianas, en particular las de origen bacteriano, incluyendo de origen estafilocócico. Idealmente, la presente invención se dirige a proteínas similares a MSCRAMM o MSCRAMM recombinantes estafilocócicas, o fragmento de las mismas, con reducción de unión a su ligando de huésped, para su uso en terapia.
MX2010008423A 2008-01-31 2009-01-29 Tratamiento de infecciones microbianas. MX2010008423A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IE20080070 2008-01-31
GBGB0801768.3A GB0801768D0 (en) 2008-01-31 2008-01-31 Treatment of microbial infections
PCT/EP2009/051033 WO2009095453A1 (en) 2008-01-31 2009-01-29 Treatment of microbial infections

Publications (1)

Publication Number Publication Date
MX2010008423A true MX2010008423A (es) 2010-09-22

Family

ID=40512496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008423A MX2010008423A (es) 2008-01-31 2009-01-29 Tratamiento de infecciones microbianas.

Country Status (22)

Country Link
US (3) US20110150918A1 (es)
EP (2) EP3117832B1 (es)
JP (1) JP5709527B2 (es)
KR (1) KR101739048B1 (es)
CN (1) CN101983067B (es)
AU (1) AU2009209598B2 (es)
BR (1) BRPI0906997A2 (es)
CA (1) CA2713241C (es)
CY (1) CY1118153T1 (es)
DK (1) DK2244722T3 (es)
EA (1) EA019516B1 (es)
ES (2) ES2960604T3 (es)
HR (1) HRP20161305T1 (es)
HU (1) HUE031614T2 (es)
LT (1) LT2244722T (es)
MX (1) MX2010008423A (es)
PL (1) PL2244722T3 (es)
PT (1) PT2244722T (es)
SG (1) SG188102A1 (es)
SI (1) SI2244722T1 (es)
WO (1) WO2009095453A1 (es)
ZA (1) ZA201005798B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007221321B2 (en) * 2006-02-22 2012-06-28 The Texas A & M University System Antibodies recognizing a highly expressed putative antigen of CA-MRSA and methods of use
AU2009209598B2 (en) 2008-01-31 2012-07-26 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Treatment of microbial infections
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
HUE038277T2 (hu) 2009-07-15 2018-10-29 Aimm Therapeutics Bv Gram-pozitív baktériumokra specifikus kötõvegyületek
WO2011007004A1 (en) 2009-07-16 2011-01-20 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Treatment of infections
GB0913680D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2488547B1 (en) 2009-10-15 2017-12-06 University Court of the University of Edinburgh Staphylococcal antigens
CN101843899B (zh) * 2010-05-24 2012-11-07 中国人民解放军第三军医大学 耐甲氧西林金黄色葡萄球菌（mrsa）重组多亚单位基因工程疫苗及其制备方法
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
WO2013159021A1 (en) * 2012-04-20 2013-10-24 The Texas A&M University System Engineered collagen binding mscramm with enhanced affinity for collagen
AU2013341361A1 (en) * 2012-11-06 2015-06-04 Medimmune, Llc Antibodies to S. aureus surface determinants
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
WO2016091904A1 (en) 2014-12-10 2016-06-16 Glaxosmithkline Biologicals Sa Method of treatment
US9238090B1 (en) 2014-12-24 2016-01-19 Fettech, Llc Tissue-based compositions
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
GB201802339D0 (en) * 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
DK3618853T3 (da) * 2018-04-24 2020-11-30 Fibriant B V Fibrinogen-gamma-prime-varianter til anvendelse til behandling af en infektion

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008341A (en) * 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
CA2367830A1 (en) * 1999-04-28 2000-11-02 The Texas A & M University System Method of inhibiting leukocyte adhesion to fibrinogen
CA2351018A1 (en) * 2001-07-09 2003-01-09 Universite De Sherbrooke Dna vaccine against staphylococcus aureus
JP2008502363A (ja) 2004-05-21 2008-01-31 ワイス Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓの改変型フィブロネクチン結合タンパク質
AU2009209598B2 (en) 2008-01-31 2012-07-26 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Treatment of microbial infections

Also Published As

Publication number Publication date
PL2244722T3 (pl) 2017-04-28
CA2713241C (en) 2022-10-04
CA2713241A1 (en) 2009-08-06
JP5709527B2 (ja) 2015-04-30
US20110150918A1 (en) 2011-06-23
EP3117832A1 (en) 2017-01-18
HUE031614T2 (en) 2017-07-28
EP2244722A1 (en) 2010-11-03
SI2244722T1 (sl) 2017-01-31
US20170202943A1 (en) 2017-07-20
HRP20161305T1 (hr) 2017-01-27
WO2009095453A1 (en) 2009-08-06
EA201001212A1 (ru) 2011-02-28
LT2244722T (lt) 2016-10-25
EA201001212A8 (ru) 2014-03-31
PT2244722T (pt) 2016-11-04
KR20110000624A (ko) 2011-01-04
US20150232518A1 (en) 2015-08-20
JP2011510952A (ja) 2011-04-07
CN101983067B (zh) 2017-07-11
ZA201005798B (en) 2013-01-30
EP3117832B1 (en) 2023-09-27
EP2244722B1 (en) 2016-07-27
BRPI0906997A2 (pt) 2015-07-07
EP3117832C0 (en) 2023-09-27
SG188102A1 (en) 2013-03-28
AU2009209598B2 (en) 2012-07-26
ES2960604T3 (es) 2024-03-05
US11512118B2 (en) 2022-11-29
DK2244722T3 (en) 2016-11-14
CY1118153T1 (el) 2017-06-28
ES2599953T3 (es) 2017-02-06
US9637525B2 (en) 2017-05-02
EA019516B1 (ru) 2014-04-30
CN101983067A (zh) 2011-03-02
KR101739048B1 (ko) 2017-05-23
AU2009209598A1 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
MX2010008423A (es) Tratamiento de infecciones microbianas.
CY1119518T1 (el) Τροποποιημενα αντιγονα φυματιωσης
WO2013025834A3 (en) Compositions and methods related to antibodies to staphylococcal protein a
NZ598524A (en) Therapeutic dll4 binding proteins
NZ602054A (en) Anti-nerve growth factor (ngf) antibody compositions
UA113712C2 (xx) Антитіло до fap і способи його застосування
MY158560A (en) Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof
MX348637B (es) Anticuerpos y composiciones anti-her3.
MX2010004482A (es) Anticuerpos anti-proteina g vsr.
MY158712A (en) Therapies for preventnig or suppressing clostridium difficile infection
MX2007003402A (es) Composicion inmunogena para su uso en vacunacion contra estafilococos.
PT2126049E (pt) Anticorpos contra citomegalovírus humano (hcmv)
WO2008083239A3 (en) Compositions and methods for stimulating an immune response
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
MX2009008928A (es) Composiciones que comprenden conjugados de polisacaridos y su uso como vacunas.
WO2008108830A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
WO2007100580A3 (en) Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use
EP2463304A3 (en) Monoclonal antibodies that neutralize anthrax toxins
WO2018027124A8 (en) ANTI-O2 ANTIBODIES AND USES THEREOF
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
WO2009115509A3 (en) Antigenic protein fragments of streptococcus pneumoniae
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3
WO2012122533A3 (en) Compositions and methods related to antibodies to staphylococcal proteins isda or isdb

Legal Events

Date Code Title Description
FG Grant or registration